NCT03676647Recruiting

Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

City of Hope Medical Center

Start Date

1/1/2027

Completion Date

9/25/2028

Summary

This trial studies how well the diagnostic deoxyribonucleic acid (DNA) methylation signature works in detecting thyroid cancer in patients with thyroid nodules. Using diagnostic testing, such as the diagnostic DNA methylation signature, may be a less invasive way to check for thyroid cancer.

Detailed Description

PRIMARY OBJECTIVES: I. To validate a novel epigenetic thyroid nodule diagnostic test, diagnostic DNA methylation signature (DDMS) in a retrospective-prospective study with leftover of fine needle aspiration biopsies. OUTLINE: Previously collected FNA aspiration specimen samples are analyzed via DDMS assay. Participants undergo FNA aspiration for collection of tissue samples for analysis via DDMS assay. After completion of study, patients are followed up yearly for 5 years.

Eligibility Criteria

Age Range: 19 years to No maximum

Inclusion Criteria: * All patients undergoing FNA for thyroid nodule diagnosis. * Any race and ethnicity are eligible for the study. * Patient should have thyroid nodule(s) with indeterminate diagnosis after FNA (Bethesda category of indeterminate FNA \[III-V\]).

Interventions

OTHER

Diagnostic DNA Methylation Signature

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Thyroid Gland Nodule

Locations

City of Hope Medical Center

Duarte, California 91010

United States